The introduction of cisplatin (DDP) has brought a major development in the chemotherapy of some malignancies. The current standard regimen is based on a combination of cisplatin and anthracyclines, with PAC (cisplatin + doxorubicin + cyclophosphamide), ADOC (cisplatin + doxorubicin + vincristine + cyclophosphamide), PE (cisplatin + etoposide), VIP (isocyclophosphamide + etoposide + cisplatin), etc. Chemotherapy can be applied in the palliative treatment of advanced thymic tumors, neoadjuvant chemotherapy and treatment of recurrent disease. When combined with radiotherapy, sequential chemoradiotherapy is generally used to avoid serious adverse effects. Chemotherapy for invasive thymoma has achieved significant efficacy in the last decade or so. Some scholars have reported in recent years that preoperative and postoperative chemotherapy improved the efficacy of stage II and stage II or higher invasive thymoma, and improved the surgical resection rate and reduced the recurrence rate. There are single agent chemotherapy and combination chemotherapy for invasive thymoma, and there are two types of combination chemotherapy, platinum-free and platinum-containing. Most scholars recommend platinum-based combination chemotherapy.